

10/573632  
IAP20 Rec'd PTO 28 MAR 2006

"Express Mail" mailing label number EV 393129147 US

Date of Deposit MAR. 28, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

QUEEN Thomas

Printed Name

Queen Thomas

Signature

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: GRAFF Jeremy Richard

For: BISINDOLYL MALEIMIDES USEFUL FOR TREATING  
PROSTATE CANCER AND AKT-MEDIATED DISEASES

Docket No.: X16348

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,



John A. Cleveland Jr.  
Attorney/Agent for Applicant(s)  
Registration No. 50,697  
Phone: 317-276-0307

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

3/24/2006

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X16348		Serial No. <b>10/573632</b>
	First Applicant GRAFF Jeremy Richard		
	Application Date US Nat'l Entry (if applicable)	Group Art Unit	

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US			
	AB	US			
	AC	US			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	BA	WO 01/30331-A2	05-03-2001	CAMERON et al.		
	BB	WO 02/02116-A2	01-10-2002	TEICHER et al.		
	BC					

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
	CA	ZHONG ET AL., Modulation of Hypoxia-inducible Factor 1 $\alpha$ Expression by the epidermal Growth Factor/Phosphatidylinositol 3-Kinase/PTEN/AKT/FRAP Pathway in Human Prostate Cancer Cells: Implications for Tumor Angiogenesis and Therapeutics, Cancer Research, March 15, 2000, 1541-1545, 60	
	CB	ROKHLIN ET AL., Bisindolylmaleimide IX Facilitates Tumor Necrosis Factor Receptor Family-mediated Cell Death and Acts as an Inhibitor of Transcription, The Journal of Biological Chemistry, September 6, 2002, 33213-33219, Vol. 277, No. 36	
	CC	TANAKA ET AL., Protein Kinase C Promotes Apoptosis in LNCaP Prostate Cancer Cells through Activation of p38 MAPK and Inhibition of the Akt Survival Pathway, The Journal of Biological Chemistry, September 5, 2003, 33753-33762, Vol. 278, No. 36	
	CD		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.